Fingerprint of the Perfect Drug
A perfect prescription would fix what ails you, and leave the rest of you well enough alone. That’s the ideal. The reality: Side effects bedevil almost all available drugs, and keep many others from ever reaching the market. A new approach for monitoring drugs’ consequences in yeast cells could help sort the silver bullets from bombs more efficiently. Acacia Biosciences-a startup in Richmond, Calif.-is systematically “knocking out,” or disabling, each yeast gene and studying what effect the loss of that specific gene has on the cell. The readout serves as a “molecular fingerprint of what the perfect drug would do,” says Acacia CEO Bruce Cohen, since such a therapeutic agent would block the function of one-and only one-gene.
Acacia is working with Eli Lilly to study test compounds in this “genome reporter matrix.” Researchers introduce candidate chemicals into thousands of yeast colonies, and record the compounds’ influence on each gene. The drug that gets closest to the “knock-out” fingerprint might be put on the inside track toward human testing.
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.